Effects of Allicin on Hypertension and Cardiac Function in Chronic Kidney Disease

Area of Science:

• Cardiovascular Research
• Nephrology
• Pharmacology

Background:

• Chronic kidney disease (CKD) is linked to hypertension and cardiac dysfunction.
• Oxidative stress and angiotensin II type 1 receptor (AT1R) pathway activation are implicated in CKD progression.
• Nrf2 pathway dysregulation contributes to impaired antioxidant defense in CKD.

Purpose of the Study:

• To investigate the effects of allicin on hypertension and cardiac function in a rat model of CKD.
• To evaluate allicin's impact on vascular response, oxidative stress, and cardiac remodeling.
• To explore the underlying mechanisms involving AT1R and Nrf2 signaling.

Main Methods:

• A rat model of CKD was established using 5/6 nephrectomy.
• Experimental groups included control, CKD, and CKD treated with allicin (40 mg/kg/day).
• Measurements included blood pressure, cardiac function, vascular reactivity, oxidative stress markers, and heart morphometrics.

Main Results:

• CKD rats exhibited hypertension, proteinuria, impaired cardiac function, and increased vascular response to angiotensin II.
• Allicin treatment significantly attenuated hypertension, improved cardiac function, and reduced vascular reactivity.
• Allicin decreased AT1R and Keap1 expression, increased Nrf2 and antioxidant enzyme expression, and reduced oxidative stress.

Conclusions:

• Allicin demonstrates significant antihypertensive, nephroprotective, and cardioprotective effects in a CKD rat model.
• These benefits are likely mediated by the downregulation of AT1R and Keap1, and activation of the Nrf2 antioxidant pathway.
• Allicin represents a potential therapeutic agent for managing complications associated with chronic kidney disease.